Combination therapy for recurrent ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests a new combination treatment for ovarian cancer that has come back after earlier treatment. It aims to see if the combination can shrink tumors or slow the disease, and it may be an option for people whose cancer has become resistant to platinum-based chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and have been diagnosed with high-grade serous ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
- Your cancer has come back after treatment, and it is either platinum-sensitive (you've had no more than 2 prior chemotherapy lines) or platinum-resistant (you've had no more than 3 prior chemotherapy lines).
- If your cancer is platinum-sensitive and you have a BRCA mutation or HRD-positive status, you must have already received a PARP inhibitor as maintenance therapy.
- Your most recent cancer treatment stopped working or caused side effects you couldn't tolerate.
- You have at least one tumor that can be measured on a scan, and you are otherwise healthy enough to participate (ECOG performance status 0-1).
- You must agree to use reliable contraception during the study and for at least 8 months after the last dose if you could become pregnant or get someone pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two experimental drugs, AK104 and AK112, for ovarian cancer that has come back after standard platinum chemotherapy. It may be an option if your cancer is a high-grade type and you have had prior treatment.
This trial tests a new combination of chemotherapy, immunotherapy, and a bladder relaxant for ovarian cancer that has come back after initial treatment. It aims to see if adding these drugs together can help control the cancer longer.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This study tests a combination of two drugs (trastuzumab rezetecan and bevacizumab) for women with ovarian cancer that has returned after initial treatment. The goal is to see if this combination helps control the cancer longer.
This trial tests a new drug combination (trastuzumab rezetecan plus carboplatin) with or without bevacizumab, compared to standard chemotherapy, for ovarian cancer that has come back after platinum-based treatment. It aims to see if this combination works better than the usual options.
This trial is testing a new drug, LBL-024, combined with chemotherapy (with or without a targeted therapy called bevacizumab) for ovarian cancer that has stopped responding to standard platinum-based treatment. The goal is to see if this combination can effectively shrink tumors and slow the disease's progression.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.